IRF1 and cervical cancer: Another recent case suggests that the PI3KCA-E545K mutation enhances PD-L1 expression by upregulating PD-L1 transcription factor interferon regulatory factor 1 and that the PIK3CA mutation may be a biomarker for pembrolizumab treatment in cervical cancer.[14]